Erratum: Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women (Cancer Letters (2004) 210 (197-203) DOI: 10.1016/j.canlet.2004.03.031;Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women

Cancer Letters

Volumn 210, Issue 2, 2004, Pages 197-203

  Noma, Chikako ^a   Miyoshi, Yasuo ^a   Taguchi, Tetsuya ^a   Tamaki, Yasuhiro ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Estrogen receptor; p53; Polymorphism

Indexed keywords

ARGINYLPROLINE; ESTROGEN RECEPTOR; PROLINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; METHODOLOGY; MUTATIONAL ANALYSIS; P53 GENE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

EID: 2942627405     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.09.018     Document Type: Erratum

References (28)

1. Cuzick J., Powles T., Veronesi U., Forbes J., Edwards R., Ashley S., Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 361:2003;296-300
2. Gail M.H., Brinton L.A., Byar D.P., Corle D.K., Green S.B., Schairer C., Mulvihill J.J. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst. 81:1989;1879-1886
3. Miyoshi Y., Ando A., Hasegawa S., Ishitobi M., Yamanura J., Irahara N., et al. Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. Eur. J. Cancer. 39:2003;2531-2537
4. Miyoshi Y., Iwao K., Ikeda N., Egawa C., Noguchi S. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int. J. Cancer. 89:2000;325-328
5. Miyoshi Y., Iwao K., Ikeda N., Egawa C., Noguchi S. Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur. J. Cancer. 36:2000;2375-2379
6. Hong C., Thompson H.J., Jiang C., Hammond G.L., Tritchler D., Yaffe M., Boyd N.F. Val 158met polymorphism in catechol-o-methyltransferase gene associated with risk factors for breast cancer. Cancer Epidemiol. Biomarkers Prev. 12:2003;838-847
7. Vasconcelos A., Medeiros R., Veiga I., Pereira D., Carrilho S., Palmeira C., et al. Analysis of estrogen receptor polymorphism in codon 325 by PCR-SSCP in breast cancer: association with lymph node metastasis. Breast J. 8:2002;226-229
8. Forsti A., Zhao C., Israelsson E., Dahlman-Wright K., Gustafsson J.A., Hemminki K. Polymorphisms in the estrogen receptor beta gene and risk of breast cancer: no association. Breast Cancer Res. Treat. 79:2003;409-413
9. Dunning A.M., Chiano M., Smith N.R., Dearden J., Gore M., Oakes S., et al. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum. Mol. Genet. 6:1997;285-289
10. Ishitobi M., Miyoshi Y., Ando A., Hasegawa S., Egawa C., Tamaki Y., Monden M., Noguchi S. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis. Clin. Cancer Res. 9:2003;1376-1380
11. Kleihues P., Schauble B., zurHausen A., Esteve J., Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am. J. Pathol. 150:1997;1-13
12. Borresen-Dale A. p53 Review article: TP53 and breast cancer. Hum. Mutat. 21:2003;292-300
13. Dumont P., Leu J., Pietra A.D. III, George D., Murphy M. The codon72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33:2003;357-365
14. Dunning A.M., Healey C.S., Pharoah P.D., Teare M.D., Ponder B.A., Easton D.F. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 8:1999;843-854
15. Sjalander A., Birgander R., Hallmans G., Cajander S., Lenner P., Athlin L., Beckman G. p53 Polymorphisms and haplotypes in breast cancer. Carcinogenesis. 17:1996;1313-1316
16. Weston A., Pan C.F., Ksieski H.B., Wallenstein S., Berkowitz G.S., Tartter P.I. p53 Haplotype determination in breast cancer. Cancer Epidemiol. Biomarkers Prev. 6:1997;105-112
17. Papadakis E., Dokianakis D., Spandidos D. p53 Codon 72 polymorphism as a risk factor in the development of breast cancer. Mol. Cell Biol. Res. Commun. 3:2000;389-392
18. Wang-Gohrke S., Rebbeck T.R., Besenfelder W., Kreienberg R., Runnebaum I.B. p53 Germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res. 18:1998;2095-2099
19. Huang X., Hamajima N., Katsuda N., Matsuo K., Hirose K., Mizutani M., et al. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer. 10:2003;307-311
20. Miyoshi Y., Takahashi Y., Egawa C., Noguchi S. Breast cancer risk associated with CYP1A1 genetic polymorphisms in Japanese women. Breast J. 8:2002;209-215
21. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J. Natl Cancer Inst. 90:1998;1371-1388
22. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst. Rev. 2001;CD000486
23. Pasqualini J.R., Chetrite C., Blacker C., Feinstein M.C., Delalonde L., Talbi M., Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 81:1996;1460-1464
24. Enger S.M., Ross R.K., Paganinis-Hill A., Carpenter C.L., Bernstein L. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies. Cancer Epidemiol. Biomarkers Prev. 9:2000;681-687
25. Langerod A., Bukholm I.R., Bregard A., Lonning P.E., Andersen T.I., Rognum T.O., et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol. Biomarkers Prev. 11:2002;1684-1688
26. Trkova M., Foretova L., Kodet R., Hedvicakova P., Sedlacek Z. A Li-Fraumeni syndrome family with retained heterozygosity for a germline TP53 mutation in two tumors. Cancer Genet. Cytogenet. 145:2003;60-64
27. Varley J.M., Thorncroft M., CcGown G., Appleby J., Kelsey A.M., Tricker K.J., et al. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene. 14:1997;865-871
28. Deng G., Chen L.C., Schott D.R., Thor A., Bhargava V., Ljung B.M., et al. Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res. 54:1994;499-505